{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:06:08Z","timestamp":1782169568724,"version":"3.54.5"},"reference-count":8,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.autrev.2023.103269","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T02:23:25Z","timestamp":1672971805000},"page":"103269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The threat of triple M and autoimmune overlap syndromes with immune checkpoint inhibitors - A series of case reports"],"prefix":"10.1016","volume":"22","author":[{"given":"Ammara","family":"Masood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Mootoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayiotis","family":"Maghsoudlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"D'Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnie","family":"Srikandarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Harries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Papa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Spicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2023.103269_bb0005","series-title":"Melanoma skin cancer statistics | Cancer Research UK [Internet]. Melanoma skin cancer statistics","author":"Cancer Research UK","year":"2017"},{"issue":"9919","key":"10.1016\/j.autrev.2023.103269_bb0010","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(13)60802-8","article-title":"Cutaneous melanoma","volume":"383","author":"Eggermont","year":"2014","journal-title":"Lancet (London, England) [Internet]"},{"issue":"2","key":"10.1016\/j.autrev.2023.103269_bb0015","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/1078155216687389","article-title":"Pembrolizumab-induced myasthenia gravis: a fatal case report","volume":"24","author":"March","year":"2018","journal-title":"J Oncol Pharm Pract [Internet]"},{"key":"10.1016\/j.autrev.2023.103269_bb0020","series-title":"Hospital Medicine [Internet]","first-page":"869","article-title":"A case of Pembrolizumab-induced Complete Heart Block and Myasthenia Gravis","author":"Jang","year":"2018"},{"issue":"suppl_4:iv119-iv142","key":"10.1016\/j.autrev.2023.103269_bb0025","first-page":"4","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.autrev.2023.103269_bb0030","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.autrev.2023.103269_bb0035","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibiton related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation [Internet]"},{"issue":"1","key":"10.1016\/j.autrev.2023.103269_bb0040","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5114\/reum.2016.58756","article-title":"Clinical characteristics of patients with anti-TIF1-\u03b3 antibodies","volume":"54","author":"Masiak","year":"2016","journal-title":"Reumatologia"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223000034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223000034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:30:36Z","timestamp":1761600636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997223000034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1568997223000034"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103269","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The threat of triple M and autoimmune overlap syndromes with immune checkpoint inhibitors - A series of case reports","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103269","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103269"}}